Cloverleaf Bio develops an RNA therapeutic platform for oncology.
Cloverleaf Bio has raised $33.0M in total funding. The most recent round was Seed. The last funding was announced in September 2026.
Cloverleaf Bio's investors include Eli Lilly, Draper Associates, AbbVie, Mission BioCapital, Boehringer Ingelheim Venture Fund.
Cloverleaf Bio is headquartered in New Haven, United States.
Cloverleaf Bio develops an RNA therapeutic platform for oncology.
Cloverleaf Bio is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Cloverleaf Bio — Funding & Investors." VCBacked, September 8, 2026, https://www.vcbacked.co/company/cloverleaf-bio. Accessed September 30, 2026.
VCBacked. (2026). Cloverleaf Bio — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/cloverleaf-bio
{{cite web |title=Cloverleaf Bio — Funding & Investors |url=https://www.vcbacked.co/company/cloverleaf-bio |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated